Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients

R D Østgård; H Glerup; A G Jurik; T W Kragstrup; K Stengaard-Pedersen; M L Hetland; K Hørslev-Petersen; P Junker; B W Deleuran

doi:10.1080/03009742.2017.1286382

Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients

R D Østgård, H Glerup, A G Jurik, T W Kragstrup, K Stengaard-Pedersen, M L Hetland, K Hørslev-Petersen, P Junker, B W Deleuran

Department of Clinical Medicine

4 Citations (Scopus)

Abstract

Objective: A reduction in haemoglobin level is a frequent complication among rheumatoid arthritis (RA) patients. Hepcidin has been linked to disturbed erythropoiesis. The objective of this study was to investigate the longitudinal changes in hepcidin in patients with early RA. Method: Hepcidin plasma concentrations were measured by enzyme-linked immunosorbent assay in patients with early RA (n = 80) and healthy volunteers (HV, n = 40). Haemoglobin and other iron-related proteins were also measured. At baseline, all patients had active disease and were treatment naïve. Patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and with additional adalimumab (ADA, n = 42) or placebo (PLA, n = 38) during 52 weeks, using a treat-to-target strategy, aiming for a 28-joint Disease Activity Score (DAS28) < 3.2. Results: At baseline, hepcidin levels [median (interquartile range)] were 9.7 ng/mL (5.2–19.4 ng/mL) in DMARD + ADA and 11.3 ng/mL (5.9–19.1 ng/mL) in DMARD + PLA. Both were significantly higher than seen in HV (6.0 ng/mL (3.3–9.3 ng/mL) (p < 0.001). After 12 months, both treatment regimens resulted in normalization of hepcidin. DAS28 correlated with hepcidin at baseline (r = 0.48, p < 0.001). No correlation was observed between levels of haemoglobin and hepcidin at baseline or during the 52 week follow-up. No change in haemoglobin levels was seen as a function of hepcidin changes. In a mixed statistical model, no single factor was connected with the regulation of haemoglobin in early RA. Conclusion: The changes in hepcidin were not associated with changes in haemoglobin levels. Thus, hepcidin could not be used as a prognostic marker in patients with early RA.

Original language	English
Journal	Scandinavian Journal of Rheumatology
Volume	46
Issue number	6
Pages (from-to)	441-445
Number of pages	5
ISSN	0300-9742
DOIs	https://doi.org/10.1080/03009742.2017.1286382
Publication status	Published - 2 Nov 2017

Keywords

Adalimumab
Adult
Aged
Antirheumatic Agents
Arthritis, Rheumatoid
Case-Control Studies
Double-Blind Method
Enzyme-Linked Immunosorbent Assay
Female
Ferritins
Hemoglobins
Hepcidins
Humans
Longitudinal Studies
Male
Middle Aged
Randomized Controlled Trials as Topic
Receptors, Transferrin
Young Adult
Journal Article

Access to Document

10.1080/03009742.2017.1286382

Cite this

Østgård, R. D., Glerup, H., Jurik, A. G., Kragstrup, T. W., Stengaard-Pedersen, K., Hetland, M. L., Hørslev-Petersen, K., Junker, P., & Deleuran, B. W. (2017). Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients. Scandinavian Journal of Rheumatology, 46(6), 441-445. https://doi.org/10.1080/03009742.2017.1286382

@article{ab0246b332bb421cb528632ab40ce383,

title = "Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients",

abstract = "Objective: A reduction in haemoglobin level is a frequent complication among rheumatoid arthritis (RA) patients. Hepcidin has been linked to disturbed erythropoiesis. The objective of this study was to investigate the longitudinal changes in hepcidin in patients with early RA. Method: Hepcidin plasma concentrations were measured by enzyme-linked immunosorbent assay in patients with early RA (n = 80) and healthy volunteers (HV, n = 40). Haemoglobin and other iron-related proteins were also measured. At baseline, all patients had active disease and were treatment na{\"i}ve. Patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and with additional adalimumab (ADA, n = 42) or placebo (PLA, n = 38) during 52 weeks, using a treat-to-target strategy, aiming for a 28-joint Disease Activity Score (DAS28) < 3.2. Results: At baseline, hepcidin levels [median (interquartile range)] were 9.7 ng/mL (5.2–19.4 ng/mL) in DMARD + ADA and 11.3 ng/mL (5.9–19.1 ng/mL) in DMARD + PLA. Both were significantly higher than seen in HV (6.0 ng/mL (3.3–9.3 ng/mL) (p < 0.001). After 12 months, both treatment regimens resulted in normalization of hepcidin. DAS28 correlated with hepcidin at baseline (r = 0.48, p < 0.001). No correlation was observed between levels of haemoglobin and hepcidin at baseline or during the 52 week follow-up. No change in haemoglobin levels was seen as a function of hepcidin changes. In a mixed statistical model, no single factor was connected with the regulation of haemoglobin in early RA. Conclusion: The changes in hepcidin were not associated with changes in haemoglobin levels. Thus, hepcidin could not be used as a prognostic marker in patients with early RA.",

keywords = "Adalimumab, Adult, Aged, Antirheumatic Agents, Arthritis, Rheumatoid, Case-Control Studies, Double-Blind Method, Enzyme-Linked Immunosorbent Assay, Female, Ferritins, Hemoglobins, Hepcidins, Humans, Longitudinal Studies, Male, Middle Aged, Randomized Controlled Trials as Topic, Receptors, Transferrin, Young Adult, Journal Article",

author = "{\O}stg{\aa}rd, {R D} and H Glerup and Jurik, {A G} and Kragstrup, {T W} and K Stengaard-Pedersen and Hetland, {M L} and K H{\o}rslev-Petersen and P Junker and Deleuran, {B W}",

year = "2017",

month = nov,

day = "2",

doi = "10.1080/03009742.2017.1286382",

language = "English",

volume = "46",

pages = "441--445",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "Taylor & Francis",

number = "6",

}

TY - JOUR

T1 - Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients

AU - Østgård, R D

AU - Glerup, H

AU - Jurik, A G

AU - Kragstrup, T W

AU - Stengaard-Pedersen, K

AU - Hetland, M L

AU - Hørslev-Petersen, K

AU - Junker, P

AU - Deleuran, B W

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Objective: A reduction in haemoglobin level is a frequent complication among rheumatoid arthritis (RA) patients. Hepcidin has been linked to disturbed erythropoiesis. The objective of this study was to investigate the longitudinal changes in hepcidin in patients with early RA. Method: Hepcidin plasma concentrations were measured by enzyme-linked immunosorbent assay in patients with early RA (n = 80) and healthy volunteers (HV, n = 40). Haemoglobin and other iron-related proteins were also measured. At baseline, all patients had active disease and were treatment naïve. Patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and with additional adalimumab (ADA, n = 42) or placebo (PLA, n = 38) during 52 weeks, using a treat-to-target strategy, aiming for a 28-joint Disease Activity Score (DAS28) < 3.2. Results: At baseline, hepcidin levels [median (interquartile range)] were 9.7 ng/mL (5.2–19.4 ng/mL) in DMARD + ADA and 11.3 ng/mL (5.9–19.1 ng/mL) in DMARD + PLA. Both were significantly higher than seen in HV (6.0 ng/mL (3.3–9.3 ng/mL) (p < 0.001). After 12 months, both treatment regimens resulted in normalization of hepcidin. DAS28 correlated with hepcidin at baseline (r = 0.48, p < 0.001). No correlation was observed between levels of haemoglobin and hepcidin at baseline or during the 52 week follow-up. No change in haemoglobin levels was seen as a function of hepcidin changes. In a mixed statistical model, no single factor was connected with the regulation of haemoglobin in early RA. Conclusion: The changes in hepcidin were not associated with changes in haemoglobin levels. Thus, hepcidin could not be used as a prognostic marker in patients with early RA.

AB - Objective: A reduction in haemoglobin level is a frequent complication among rheumatoid arthritis (RA) patients. Hepcidin has been linked to disturbed erythropoiesis. The objective of this study was to investigate the longitudinal changes in hepcidin in patients with early RA. Method: Hepcidin plasma concentrations were measured by enzyme-linked immunosorbent assay in patients with early RA (n = 80) and healthy volunteers (HV, n = 40). Haemoglobin and other iron-related proteins were also measured. At baseline, all patients had active disease and were treatment naïve. Patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and with additional adalimumab (ADA, n = 42) or placebo (PLA, n = 38) during 52 weeks, using a treat-to-target strategy, aiming for a 28-joint Disease Activity Score (DAS28) < 3.2. Results: At baseline, hepcidin levels [median (interquartile range)] were 9.7 ng/mL (5.2–19.4 ng/mL) in DMARD + ADA and 11.3 ng/mL (5.9–19.1 ng/mL) in DMARD + PLA. Both were significantly higher than seen in HV (6.0 ng/mL (3.3–9.3 ng/mL) (p < 0.001). After 12 months, both treatment regimens resulted in normalization of hepcidin. DAS28 correlated with hepcidin at baseline (r = 0.48, p < 0.001). No correlation was observed between levels of haemoglobin and hepcidin at baseline or during the 52 week follow-up. No change in haemoglobin levels was seen as a function of hepcidin changes. In a mixed statistical model, no single factor was connected with the regulation of haemoglobin in early RA. Conclusion: The changes in hepcidin were not associated with changes in haemoglobin levels. Thus, hepcidin could not be used as a prognostic marker in patients with early RA.

KW - Adalimumab

KW - Adult

KW - Aged

KW - Antirheumatic Agents

KW - Arthritis, Rheumatoid

KW - Case-Control Studies

KW - Double-Blind Method

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - Ferritins

KW - Hemoglobins

KW - Hepcidins

KW - Humans

KW - Longitudinal Studies

KW - Male

KW - Middle Aged

KW - Randomized Controlled Trials as Topic

KW - Receptors, Transferrin

KW - Young Adult

KW - Journal Article

U2 - 10.1080/03009742.2017.1286382

DO - 10.1080/03009742.2017.1286382

M3 - Journal article

C2 - 28482738

SN - 0300-9742

VL - 46

SP - 441

EP - 445

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

IS - 6

ER -

Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this